Monika Schäfer-korting

Biography

1971-1975 Studied pharmacy at the Goethe University Frankfurt 1976 Approbation as a pharmacist 1977 promotion 1989 Habilitation 1994 Appointed to the newly established Pharmacology Chair at the Faculty of Pharmacy, Freie Universität Berlin since 1995 Advisory Board of the Association of Professors at Pharmaceutical Institutes of Higher Education of the Federal Republic of Germany Head of the Society for Dermopharmacy 1997-99 Vice-President of Freie Universität Berlin since 2000 Scientific Director of ScienceFair Berlin 2001-2005 Prodecan of the Department of Biology, Chemistry, Pharmacy, FUB 2002-2008 Spokesperson of the DFG research group "Innovative drugs and carrier systems - Integrative optimization for the treatment of inflammatory and hyperproliferative diseases" (FG 463) Coordinator of the BMBF Collaborative Project: "Validation study for the examination of skin penetration with the aid of biotechnologically produced skin models" (FKZ 0312881) since 2005 Member / Chairman of the Scientific Advisory Board of the Federal Institute for Risk Assessment, Berlin 2006 - (2010) Member of the BMBF-funded research group "NanoDerm" since 2007 Vice-President of Freie Universität Berlin since 2009 Member of the BMBF Collaborative Project "Skin Metabolism" since 2010 Member of the EU Coordinating Group "Accelerating the transition to a toxicity pathway-based paradigm for chemical safety assessment" ( AXLR8) since 2012 Member of the Helmholtz Virtual Institute "Functional Biomaterials for Medicine".

Research Interest

The focus is on the improvement of the therapy of skin diseases by testing potential new pharmaceuticals with regard to the skin, elucidating the molecular mechanisms of action of known and new drugs, investigating the uptake and metabolization of such substances in human skin, but also with the aid of two- and three-dimensional skin models Models of skin diseases and an increase in the benefit / risk ratio by means of particulate carrier systems. Pharmacokinetic experiments also show a significant contribution of the metabolism of these drugs in the skin to the differences in the benefit / risk ratio. It is precisely these studies which point to the particular importance of the still widely unknown skin metabolism. After clinical studies with a liposomal glucocorticoid have already pointed out progress by particulate carrier systems, systematic investigations are now being carried out on the skin-specific drug application by means of complex carrier systems.